This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:
Results from the AURORAS-1 Phase I clinical trial of an anticancer drug called ERAS-0015 have shown that it is safe and has caused tumors to shrink in hard-to-treat diseases such as lung and pancreatic cancer.
Presented at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain, the findings from 148 patients are significant because ERAS-0015 targets tumors whose growth is driven by mutations in the RAS gene. Until recently, it was not thought possible to design drugs that could target these mutations successfully.
Dr. Judy Wang, a medical oncologist at Florida Cancer Specialists and Research Institute, Sarasota, U.S., told the symposium, "AURORAS-1 has enrolled patients who have tried a number of other treatments for their cancer. In this context, ERAS-0015 treatment caused a 44% response rate in patients with RAS-mutant pancreatic cancer and a 60% response rate in patients with RAS-mutant lung cancer.
"A 'response' means the patients experienced considerable tumor shrinkage, and these response rates are important as they show clinically meaningful activity from ERAS-0015 treatment in patient groups that have few if any therapeutic options to address their cancer.
"In addition to this, ERAS-0015 was well tolerated with few severe side effects."
ERAS-0015 is a "pan-RAS molecular glue," which means that it brings proteins together at the molecular level in a way that blocks tumor growth signals from several different cancer-driving RAS mutations.
Source link







